Skip to main content
SpringerLink
Log in

Blood coagulation factor VIII: An overview

  • Review
  • Published:
Journal of Biosciences Aims and scope Submit manuscript

Abstract

Factor VIII (FVIII) functions as a co-factor in the blood coagulation cascade for the proteolytic activation of factor X by factor IXa. Deficiency of FVIII causes hemophilia A, the most commonly inherited bleeding disorder. This review highlights current knowledge on selected aspects of FVIII in which both the scientist and the clinician should be interested.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

FVIII:

Factor VIII

ER:

endoplasmic reticulum

ITI:

immune tolerance induction

vWF:

von Willebrant factor

References

  • Abshire T C, Brackmann H H, Scharrer I, Hoots K, Gazengel C, Powell J S, Goring E, Kellermann E and Voshurgh E 2000 Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy;Thromb. Haemost. 38 811–816

    Google Scholar 

  • Antonarakis S E, Kazazian H H and Tuddenham E G 1995 Molecular etiology of factor VIII deficiency in hemophilia A;Hum. Mutat. 5 1–22

    Article  PubMed  CAS  Google Scholar 

  • Antonarakis S E, Rossiter J P, Young M, Horst J, Demoerloose P, Sammer S S, Ketterling R P and Kazazian H H Jr, Negrier C, Vinciguerra C 1995 Factor VIII gene inversions in severe hemophilia A: results of an international consortium study;Blood 86 2206–2212

    PubMed  CAS  Google Scholar 

  • Azzi A, De Santis R, Morfini M, Zakrzewska K, Musso R, Santagostina E and Castaman G 2001 TT virus contaminates first generation recombinant factor VIII concentrates;Blood 98 2571–2573

    Article  PubMed  CAS  Google Scholar 

  • Azzi A, Morfini M and Mannucci P M 1999 The transfusion associated transmission of parvovirus B19;Transfus. Med. Rev. 13 194–204

    Article  PubMed  CAS  Google Scholar 

  • Bowen D J 2002 Haemophilia A and Haemophilia B: molecular insights;Mol. Pathal. 55 127–144

    Article  CAS  Google Scholar 

  • Dimichele D M 1998 Immune tolerance: a synopsis of the international experience;Haemophilia 4 568–573

    Article  CAS  Google Scholar 

  • Eaton D, Rodriguez H and Vehar G A 1986 Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity;Biochemistry 25 505–512

    Article  PubMed  CAS  Google Scholar 

  • Foster P A and Zimmerman T S 1989 Factor VIII structure and function;Blood Rev. 3 180–191

    Article  PubMed  CAS  Google Scholar 

  • Fricke W A and Lamb M A 1993 Viral safety of clotting factors;Semin. Thromb. Hemost. 19 54–61

    Article  PubMed  CAS  Google Scholar 

  • Fulcher C A, Roberts J R and Zimmerman T S 1983 Thrombin proteolysis of purified factor VIII. Corelation of activation with generation of a specific polypeptide;Blood 61 807–811

    PubMed  CAS  Google Scholar 

  • Ghirardini A, Puopolo M, Chiarotti F and Mariani G 1996 The international registry of immune tolerance: 1994; Update;Vox Sang. 70 42–46

    PubMed  Google Scholar 

  • Gilles J G, Lavend’homme R, Peerlinck K, Jacquemin M G, Hoxlaerts M, Joorieux S, Mazurier C, Vermylen J and Saint-Remy J M 1999 Some factor VIII (FVIII) inhibitors recognize a FVIII epitope(s) that is present only on FVIII - vWF complexes;Thromb. Haemost. 82 40–45

    PubMed  CAS  Google Scholar 

  • Gitschier J, Wood W I, Goralka T M, Wion K L, Chen E Y, Eaton D H, Vehar G A, Capon D J and Lawn RM 1984 Characterization of the human factor VIII gene;Nature (London) 312 326–330

    Article  CAS  Google Scholar 

  • Hoeben R C, Einerhand M P W, Briet E, Van Ormondt H, Valerio D and Van der Eb A J 1992 Towards gene therapy in hemophilia A: retrovirus-mediated transfer of a factor VIII gene into murine haemotopoietic progenitor cells;Thromb. Haemost. 67 341–345

    PubMed  CAS  Google Scholar 

  • Hoeben R C, Fallaux F J, Van Tilburg N H, Cramer S J, Van Briet E and Van Der Eb A J 1993 Towards gene therapy of hemophilia A: long term persistence of Factor VIII secreting fibroblasts after transplantation into immunodeficient mice;Hum. Gene Ther. 4 179–186

    PubMed  CAS  Google Scholar 

  • Jacquemin M, Lavend’homme R, Benhida A, Vanzieleghem B, d’Oiron R, Lavergne J M, Brackmann H H, Schwaab R, Vanden Driessche T, Chuah M K L, Hoylaert S M, Gilles J G G, Peerlink K, Vermylen J and Saaint-Remy J M R 2000 A novel cause of mild/moderate hemophilia A: Mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor;Blood 96 958–965

    PubMed  CAS  Google Scholar 

  • Kaufman R J 1992 Biological regulation of factor VIII activity;Annu. Rev. Med. 43 325–339

    Article  PubMed  CAS  Google Scholar 

  • Kaufman R J 1999 Advances toward gene therapy for hemophilia at the milennium;Hum. Gene Ther. 10 2091–2107

    Article  PubMed  CAS  Google Scholar 

  • Kreil T R, Zimmermann K, Pable S, Schwarz H P, Dorner F, Azzi A and Morfini 2002 TT virus does not contaminate first generation recombinant factor VIII concentrate;Blood 100 2271–2272

    Article  PubMed  CAS  Google Scholar 

  • Lakich D, Kazazian H H Jr, Antonarakis S E and Gitschier J 1993 Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A;Nat. Genet. 5 236–241

    Article  PubMed  CAS  Google Scholar 

  • Lenting P J, van Mourik J A and Mertens K 1998 The life cycle of coagulation factor VIII in view of its structure and function;Blood 92 3983–3996

    PubMed  CAS  Google Scholar 

  • Leyte A, van Schijndel H B, Niehrs C, Hunter W B, Verbeet M P, Mertens K and van Mourik J A 1991 Sulphation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor;J. Biol. Chem. 266 740–746

    PubMed  CAS  Google Scholar 

  • Lozier J N and Kessler C N 2000 Clinical aspects and therapy of hemophilia; inHematology: basic principles and practice (eds) R Hoffman, E Benz Jr and S Shattil (New York: Churchill Livingstone) pp 1883–1904

    Google Scholar 

  • Lusher J M, Arkin S, Abildgaard C F and Schwartz R S 1993 Recombinant factor VIII for the treatment of previously untreated patients with haemophilia A - Safety, efficacy, and development of inhibitors;N. Engl. J. Med. 328 453–459

    Article  PubMed  CAS  Google Scholar 

  • Lusher J M, Petrini P and Angiolillo A 2000 Antibody and inhabitor patterns in previously untreated patients (PUPs) treated exclusively with B-domain deleted factor VIII (BDDrFVIII);Blood 96 266

    Google Scholar 

  • Lynch C M, Israel D I, Kaufman R J and Miller D 1993 Sequences in the coding region of clotting factor VIII act as dominant inhibitors of RNA accumulation and protein production;Hum. Gene Ther. 4 259–273

    Article  PubMed  CAS  Google Scholar 

  • Mannucci P M and Tuddenham E G D 2001 Medical Progress: The haemophilias - from Royal genes to gene therapy;N. Engl. J. Med. 344 1773–1779

    Article  PubMed  CAS  Google Scholar 

  • Mariani G, Ghirardini A and Bellocco R 1994 Immune tolerance in hemophilia - Principal results from the international registry. Report of the factor VIII and IX subcommittee;Thromb. Haemost. 72 155–158

    PubMed  CAS  Google Scholar 

  • Marquette K A, Pittman D D and Kaufman R J 1995 A 110 amino acid region within the A1-domain of coagulation factor VIII inhibits secretion from mammalian cells;J. Biol. Chem. 270 10297–10303

    Article  PubMed  CAS  Google Scholar 

  • Martin R B 1986Metal ions in biological system (ed.) H Segel (New York: Marcel Dekker) pp 20–21

    Google Scholar 

  • Matsui H, Sugimoto M, Tsuji S, Shima M, Giddings J and Yoshioka A 1999 Transient hypoplastic anemia caused by primary human parvovirus B19 infection in previously untreated patient with hemophilla transfused with a plasma derived monoclonal antibody purified factor VIII concentrate;J. Pediatr. Hematol. Oncol. 21 74–76

    Article  PubMed  CAS  Google Scholar 

  • Mauser-Bunschoten E P, Roosendaal F R, Nieuwenhuis H P, Rosendaal G, Briet E and van den Berg H M 1994 Clinical course of factor VIII inhibitors developed after exposure to a pasteurised Dutch concentrate compared to classic inhibitors in haemophilia A;Thromb. Haemost. 71 703–706

    PubMed  CAS  Google Scholar 

  • McEvoy G K, 2001AHFS Drug Information (Bethesda: American Society of Health System Pharmacists) pp 1412–1428

    Google Scholar 

  • Naylor J, Brinke A, Hassock S, Green P M and Giannelli F 1993 Characteristic mRNA abnormality found in half the patients with severe haemophilia A is due to large DNA inversions;Hum. Mol. Genet. 2 1973–1978

    Article  Google Scholar 

  • Nishizawa T, Okamoto N, Konishi K, Yoshizawa H, Miyakawa Y and Mayumi M 1997 A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology;Biochem. Biophys. Res. Commun. 241 92–97

    Article  PubMed  CAS  Google Scholar 

  • Osterberg T, Fatouros A and Mikaelsson M 1997 Development of a freeze dried albumin free formulation of recombinant factor VIII SQ;Pharm. Res. 14 892–898

    Article  PubMed  CAS  Google Scholar 

  • Peerlinck K, Arnout J, di Giampattista M, Gillies J G, Laub R, Jacquemin M, Saint J M R and Vermylen J 1997 Factor VIII inhibitors in previously treated haemophilia A patients with a double virus inactivated plasma derived concentrate;Thromb. Haemost. 77 80–86

    PubMed  CAS  Google Scholar 

  • Peerlinck K, Arnout J, Gilles J G, Saint-Remy J M and Vermylen J 1993 A higher than expected incidence of factor VIII inhibitor in multitransfused haemophilia A patients treated with a intermediate purity pasteurized factor VIII concentrate;Thromb. Haemost. 69 115–118

    PubMed  CAS  Google Scholar 

  • Pipe S W, Morris J A, Shah J and Kaufman R J 1998 Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin;J. Biol. Chem. 273 8537–8544

    Article  PubMed  CAS  Google Scholar 

  • Pitmann D D and Kaufman R J 1988 Proteolytic requirements for thrombin activation of antihemophilic factor VIII;Proc. Natl. Acad. Sci. USA 85 2429–2433

    Article  Google Scholar 

  • Pittman D D, Wang J H and Kaufman R J 1992 Identification and functional importance of tyrosine sulfate residues within recombinant factor VIII;Biochemistry 31 3315–3325

    Article  PubMed  CAS  Google Scholar 

  • Richard K A 1997 The diagnosis of hemophilia A and B and von Willebrand’s disease; inHemophilia (eds) C D Forbes, L M Aledort and R Madhok (London: Chapman and Hall Medical) pp 53–62

    Google Scholar 

  • Roelse J C, De Laaf R T, Timmermans S M, Peters M, Van Mourik J A and Voorberg J 2000 Intracellular accumulation of factor VIII induced by missense mutations Arg 593 - Cys and Asn 618 - Ser explains cross-reacting material reduced haemophilia A;Br. J. Haematol. 108 241–246

    Article  PubMed  CAS  Google Scholar 

  • Rosendaal F R 1997 Factor VIII inhibitors on a SD treated and pasteurised concentrate associated with specific batches and batch characteristics;Thromb. Haemost. 78 590–594

    Google Scholar 

  • Rosendaial F R, Nieuwenhuis H K, van den Berg H M, Heijboer H, Mauser-Bunschoten E P, van der Meer J, Smit C, Strengers P F and Briet E 1993 A sudden increase in factor VIII inhibiter development in multitransfused hemophilia A patients in the Netherlands. Dutch Hemophilia study Group;Blood 81 2180–2186

    Google Scholar 

  • Roth D A, Tawa N E Jr, O’Brien J M, Treco D A and Selden R F 2001 Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe Hemophilia A;N. Engl. J. Med. 344 1735–1742

    Article  PubMed  CAS  Google Scholar 

  • Saenko E L and Scandella D 1997 The acidic region of the factor VIII light chain and the C2 domain together from the high affinity binding site for von Willebrand factor;J. Biol. Chem. 272 18007–18014

    Article  PubMed  CAS  Google Scholar 

  • Saenko E L, Shima M, Rejalakshmi K J and Scandella D 1994 A role for the C2 domain of factor VIII in binding to von Willebrand factor;J. Biol. Chem. 269 11601–11605

    PubMed  CAS  Google Scholar 

  • Scandella D 2000 Properties of anti factor VIII inhibitor antibodies in hemophilia A patients;Semin. Thromb. Hemost. 26 137–142

    Article  PubMed  CAS  Google Scholar 

  • Schwaab R, Brackmann H H, Meyer C, Seehafer J, Kirchgesser M, Hacck A, Olek K, Tuddenham E G D and Oldenburg J 1995 Haemophilia A: Mutation type determines risk of inhibitor formation;J. Thromb. Haemost. 74 1402–1406

    CAS  Google Scholar 

  • Srivastava A, Chuansumrit A, Chandy M, Duraiswamy G and Karagus C 1998 Management of hemophilia in the developing countries;Hemophilia 4 474–480

    Article  CAS  Google Scholar 

  • Swaroop M, Moussalli M, Pipe S W and Kaufman R J 1997 Mutagenesis of a potential immunoglobulin-binding-protein-binding site enhances secretion of coagulation factor VIII;J. Biol. Chem. 272 24121–24124

    Article  PubMed  CAS  Google Scholar 

  • Tuddenham E G D, Cooper D N, Gritschier J, Higuchim, Hoyer L W, Yoshioka A, Peake I R, Schwaab R, Olekk, Kazazian H H 1991 Haemophilia A: database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene;Nucleic Acids Res. 19 4821–4833

    Article  PubMed  CAS  Google Scholar 

  • Vehar G A, Keyt B, Eaton D, Rodriguez H, O’Brien D P, Rotblat F, Oppermann H, Keck R, Wood W I, Harkins R N, Tuddenham E G D, Lawn R M and Capon D J 1984 Structure of human Factor VIII;Nature (London) 312 337–342

    Article  CAS  Google Scholar 

  • Viot A J, Koppelman S J, van den Berg M H, Bouma B N and Sixma J J 1995 The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor;Blood 85 3150–3157

    Google Scholar 

  • Wacey A I, Kemball-Cook G, Kazazian H H, Antonarakis S E, Schivaab R, Lindey P and Tuddenhum E G 1996 The haemophilia A mutation search test and resource site, home page of the factor VIII mutation database: HAMSTeRS;Nucleic Acids Res. 24 100–102

    Article  PubMed  CAS  Google Scholar 

  • Wion K L, Kelly D, Summerfield J A, Tuddenham E G D and Lawn R M 1985 Distribution of factor VIII mRNA and antigen in human liver and other tissues;Nature (London) 317 726–729

    Article  CAS  Google Scholar 

  • Yee T T, Lee C A and Pasi K J 1995 Life threatening human parvovirus B19 infection in immunocompetent haemophilia;Lancet 345 794–795

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research and Development Division, Hindustan Antibiotics Ltd., 411 018, Pimpri, Pune, India

    G. M. Bhopale & R. K. Nanda

Authors
  1. G. M. Bhopale
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. K. Nanda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. M. Bhopale.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bhopale, G.M., Nanda, R.K. Blood coagulation factor VIII: An overview. J Biosci 28, 783–789 (2003). https://doi.org/10.1007/BF02708439

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02708439

Keywords

Search

Navigation